Neil Graham
Director/Board Member bij ASLAN PHARMACEUTICALS LIMITED
Vermogen: - $ op 31-03-2024
Actieve functies van Neil Graham
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ASLAN PHARMACEUTICALS LIMITED | Director/Board Member | 18-02-2021 | - |
Independent Dir/Board Member | 18-02-2021 | - | |
ZURA BIO LIMITED | Director/Board Member | 01-03-2023 | - |
Independent Dir/Board Member | 01-03-2023 | - | |
ALLAKOS INC. | Director/Board Member | 30-08-2023 | - |
Independent Dir/Board Member | 30-08-2023 | - | |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Director/Board Member | - | - |
Independent Dir/Board Member | - | - |
Loopbaan van Neil Graham
Eerdere bekende functies van Neil Graham
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SYNTARA LIMITED | Director/Board Member | 04-05-2020 | 03-10-2023 |
Independent Dir/Board Member | 04-05-2020 | 03-10-2023 | |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | 13-01-2021 | 18-07-2022 |
REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2009 | 01-01-2020 |
VERTEX, INC. | Corporate Officer/Principal | 01-04-2007 | 01-11-2009 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01-06-2005 | 01-02-2007 |
░░░ ░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░░ ░░ ░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Opleiding van Neil Graham
University of Adelaide | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Australië | 3 |
Singapore | 3 |
Operationeel
Corporate Officer/Principal | 6 |
Director/Board Member | 5 |
Independent Dir/Board Member | 5 |
Sectoraal
Health Technology | 12 |
Consumer Services | 3 |
Technology Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 8 |
---|---|
REGENERON PHARMACEUTICALS, INC. | Health Technology |
SYNTARA LIMITED | Health Technology |
XTL BIOPHARMACEUTICALS LTD. | Health Technology |
VERTEX, INC. | Technology Services |
ALLAKOS INC. | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
ASLAN PHARMACEUTICALS LIMITED | Health Technology |
ZURA BIO LIMITED | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Glaxo Wellcome Plc | Health Technology |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Health Technology |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Neil Graham
- Ervaring